File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: The clinical outcome of prostate ductal adenocarcinoma: a multicentre matched cohort comparative study

TitleThe clinical outcome of prostate ductal adenocarcinoma: a multicentre matched cohort comparative study
Authors
Issue Date2018
PublisherSpringer Verlag. The Publication web site is located at https://link.springer.com/journal/345
Citation
38th Congress of the Société Internationale d'Urologie (SIU). Dragon City, Seoul, South Korea, 4-7 October 2018. Abstract Book in World Journal of Urology, 2018, v. 36 n. Suppl. 1, p. 151-152 How to Cite?
AbstractIntroduction and Objective: Prostate Ductal Adenocarcinoma (PDA) is a rare variant of prostate cancer (PCa). There are conflicting reports regarding the oncological outcome and prognosis of PDA. To date there is no consensus on what the best treatment option is. Materials and Methods: All patients who were diagnosed with PDA in three institutions from London (UK), Hong Kong and Kingston (Jamaica) during 2005-2015 period were included. Treatment included radical surgery, radical radiotherapy or hormone manipulation. Patients who were diagnosed with at least Gleason 8 prostate acinar adenocarcinoma (PAA) served as control groups. Results: Of 9812 patients who were diagnosed with PCa, 157 (1.8%) had PDA and 958 had (PAA). PSA at presentation was lower for PDA. 346 (247-PAA, 99-PDA) patients were treated with radical prostatectomy. 314 (295-PAA, 19-PDA), had radical radiotherapy. 449 (416-PAA, 33-PDA) had hormone treatment. In the surgery group positive margin were 51% (PDA) vs 54% (PAA), p=0.13. At follow up 57% (PDA) vs 46% (PAA) had biochemical recurrence, and 14% (PDA) vs 5.3% (PAA), p=0.08 developed distant metastasis and 4.5% (PDA) vs 5.3% (PAA) have died. In the radiotherapy group 16% (PDA) vs 22% (PAA) had biochemical recurrence, 16% (PDA) vs 9% (PAA), p=0.01 developed distant metastasis and 17% (PDA) vs 18% (PAA), p=0.76 have died. In the hormone group 71% (PDA) vs 47% (PAA) developed metastasis at 32 months and 71% (PDA) vs 45% (PAA) have died. The mean follow-up for all groups is 71 months. Conclusion: PDA patients had higher risk of metastasis compared to the acinar group regardless of the treatment offered. An early adjuvant treatment may be required in prostate ductal cancer.
DescriptionModerated ePosters - Session 15: Prostate Cancer - no. MP-15.06
Persistent Identifierhttp://hdl.handle.net/10722/266477
ISSN
2017 Impact Factor: 2.981
2015 SCImago Journal Rankings: 1.072

 

DC FieldValueLanguage
dc.contributor.authorElhage, O-
dc.contributor.authorLam, PW-
dc.contributor.authorMorrison, B-
dc.contributor.authorTsu, JHL-
dc.contributor.authorSuleman, MT-
dc.contributor.authorKiberu, Y-
dc.contributor.authorKhan, N-
dc.contributor.authorPersad, R-
dc.contributor.authorChandra, A-
dc.contributor.authorDasgupta, P-
dc.date.accessioned2019-01-18T08:20:26Z-
dc.date.available2019-01-18T08:20:26Z-
dc.date.issued2018-
dc.identifier.citation38th Congress of the Société Internationale d'Urologie (SIU). Dragon City, Seoul, South Korea, 4-7 October 2018. Abstract Book in World Journal of Urology, 2018, v. 36 n. Suppl. 1, p. 151-152-
dc.identifier.issn0724-4983-
dc.identifier.urihttp://hdl.handle.net/10722/266477-
dc.descriptionModerated ePosters - Session 15: Prostate Cancer - no. MP-15.06-
dc.description.abstractIntroduction and Objective: Prostate Ductal Adenocarcinoma (PDA) is a rare variant of prostate cancer (PCa). There are conflicting reports regarding the oncological outcome and prognosis of PDA. To date there is no consensus on what the best treatment option is. Materials and Methods: All patients who were diagnosed with PDA in three institutions from London (UK), Hong Kong and Kingston (Jamaica) during 2005-2015 period were included. Treatment included radical surgery, radical radiotherapy or hormone manipulation. Patients who were diagnosed with at least Gleason 8 prostate acinar adenocarcinoma (PAA) served as control groups. Results: Of 9812 patients who were diagnosed with PCa, 157 (1.8%) had PDA and 958 had (PAA). PSA at presentation was lower for PDA. 346 (247-PAA, 99-PDA) patients were treated with radical prostatectomy. 314 (295-PAA, 19-PDA), had radical radiotherapy. 449 (416-PAA, 33-PDA) had hormone treatment. In the surgery group positive margin were 51% (PDA) vs 54% (PAA), p=0.13. At follow up 57% (PDA) vs 46% (PAA) had biochemical recurrence, and 14% (PDA) vs 5.3% (PAA), p=0.08 developed distant metastasis and 4.5% (PDA) vs 5.3% (PAA) have died. In the radiotherapy group 16% (PDA) vs 22% (PAA) had biochemical recurrence, 16% (PDA) vs 9% (PAA), p=0.01 developed distant metastasis and 17% (PDA) vs 18% (PAA), p=0.76 have died. In the hormone group 71% (PDA) vs 47% (PAA) developed metastasis at 32 months and 71% (PDA) vs 45% (PAA) have died. The mean follow-up for all groups is 71 months. Conclusion: PDA patients had higher risk of metastasis compared to the acinar group regardless of the treatment offered. An early adjuvant treatment may be required in prostate ductal cancer.-
dc.languageeng-
dc.publisherSpringer Verlag. The Publication web site is located at https://link.springer.com/journal/345-
dc.relation.ispartofWorld Journal of Urology-
dc.relation.ispartofThe 38th Congress of the Societe International d'Urologie, 2018-
dc.titleThe clinical outcome of prostate ductal adenocarcinoma: a multicentre matched cohort comparative study-
dc.typeConference_Paper-
dc.identifier.emailLam, PW: lamwayne@hku.hk-
dc.identifier.emailTsu, JHL: jamestsu@hku.hk-
dc.identifier.authorityLam, PW=rp02305-
dc.identifier.hkuros296734-
dc.identifier.volume36-
dc.identifier.issueSuppl. 1-
dc.identifier.spage151-
dc.identifier.epage152-
dc.publisher.placeGermany-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats